HR 7693119th CongressIn Committee
Leo’s Law
Standard Summary
Balanced plain-English summary
Leo's Law would extend by 180 days several exclusivity and approval-delay periods under federal drug law for certain orphan drugs whose development was affected by the COVID-19 emergency, provided the periods have not expired.
Key Points
- 1Extends certain 12-year, 5-year, 3-year, and 7-year orphan-drug exclusivity periods by 180 days if still active.
- 2Adds conforming 180-day extensions for related 4-year, 48-month, and 7.5-year periods.
- 3Defines covered orphan drugs by COVID-19 emergency-period investigational applications, approval, and lack of non-rare approved indications.
- 4Takes effect immediately without waiting for implementing guidance or regulations.
Impact Areas
Rare disease patientsOrphan drug manufacturersGeneric and biosimilar developersFDAHealth insurers and payers
Generated by deepseek/deepseek-v4.1-flash-1017Nov 18, 2026